Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) - Net Assets
Based on the latest financial reports, Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has net assets worth CN¥2.50 Billion CNY (≈ $366.09 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.80 Billion ≈ $556.41 Million USD) and total liabilities (CN¥1.30 Billion ≈ $190.32 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 301096 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.50 Billion |
| % of Total Assets | 65.8% |
| Annual Growth Rate | 44.02% |
| 5-Year Change | 7.39% |
| 10-Year Change | N/A |
| Growth Volatility | 215.09 |
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Net Assets Trend (2019–2025)
This chart illustrates how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. See Hangzhou Bio-Sincerity Pharma-Tech Co.Lt (301096) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2025)
The table below shows the annual net assets of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2025. For live valuation and market cap data, see 301096 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.49 Billion ≈ $364.21 Million |
-3.51% |
| 2024-12-31 | CN¥2.58 Billion ≈ $377.45 Million |
-3.90% |
| 2023-12-31 | CN¥2.68 Billion ≈ $392.77 Million |
+8.13% |
| 2022-12-31 | CN¥2.48 Billion ≈ $363.23 Million |
+7.10% |
| 2021-12-31 | CN¥2.32 Billion ≈ $339.16 Million |
+582.61% |
| 2020-12-31 | CN¥339.54 Million ≈ $49.69 Million |
+21.82% |
| 2019-12-31 | CN¥278.74 Million ≈ $40.79 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1185.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥268.48 Million | 10.79% |
| Other Components | CN¥2.22 Billion | 89.21% |
| Total Equity | CN¥2.49 Billion | 100.00% |
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Competitors by Market Cap
The table below lists competitors of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vaudoise Assurances Holding SA
SW:VAHN
|
$890.89 Million |
|
Irish Continental Group PLC
IR:IR5B
|
$890.98 Million |
|
Vulcabras Azaleia S.A
SA:VULC3
|
$891.24 Million |
|
Qiming Information Technology Co Ltd
SHE:002232
|
$891.37 Million |
|
Wuhan Zhongyuan Huadian Sci Tech
SHE:300018
|
$890.59 Million |
|
Sparebanken Sor
OL:SOR
|
$890.43 Million |
|
Jiangsu Nanfang Bearing Co Ltd
SHE:002553
|
$890.01 Million |
|
Zhang Xiaoquan Inc.
SHE:301055
|
$889.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,579,389,784 to 2,488,953,770, a change of -90,436,014 (-3.5%).
- Net loss of 90,395,530 reduced equity.
- Dividend payments of 20,521,855 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-90.40 Million | -3.63% |
| Dividends Paid | CN¥20.52 Million | -0.82% |
| Other Changes | CN¥20.48 Million | +0.82% |
| Total Change | CN¥- | -3.51% |
Book Value vs Market Value Analysis
This analysis compares Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.45x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 16.23x to 2.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥3.43 | CN¥55.72 | x |
| 2020-12-31 | CN¥4.19 | CN¥55.72 | x |
| 2021-12-31 | CN¥21.43 | CN¥55.72 | x |
| 2022-12-31 | CN¥22.95 | CN¥55.72 | x |
| 2023-12-31 | CN¥24.64 | CN¥55.72 | x |
| 2024-12-31 | CN¥23.61 | CN¥55.72 | x |
| 2025-12-31 | CN¥22.79 | CN¥55.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.33%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.48x
- Recent ROE (-3.63%) is below the historical average (7.13%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 15.94% | 28.38% | 0.41x | 1.36x | CN¥16.55 Million |
| 2020 | 16.91% | 27.70% | 0.31x | 1.94x | CN¥23.45 Million |
| 2021 | 4.79% | 29.68% | 0.13x | 1.26x | CN¥-120.70 Million |
| 2022 | 7.82% | 31.97% | 0.21x | 1.18x | CN¥-54.09 Million |
| 2023 | 10.13% | 26.73% | 0.28x | 1.37x | CN¥3.55 Million |
| 2024 | -2.04% | -6.58% | 0.22x | 1.44x | CN¥-310.68 Million |
| 2025 | -3.63% | -13.33% | 0.18x | 1.48x | CN¥-339.29 Million |
Industry Comparison
This section compares Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $4,891,571,066
- Average return on equity (ROE) among peers: 6.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) | CN¥2.50 Billion | 15.94% | 0.52x | $890.60 Million |
| Zhejiang Int'L Group Co Ltd (000411) | $3.21 Billion | 10.69% | 2.51x | $732.38 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $1.98 Billion | 1.15% | 0.48x | $308.51 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $-153.68 Million | 0.00% | 0.00x | $750.55 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $134.18 Million | 12.98% | 0.83x | $302.41 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $9.15 Billion | 2.09% | 0.37x | $1.73 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $758.22 Million | 2.72% | 0.11x | $247.30 Million |
| Sichuan Kelun Pharmaceutical Co Ltd (002422) | $29.29 Billion | 5.81% | 0.36x | $8.36 Billion |
| Chongqing Lummy Pharmaceutical (300006) | $1.65 Billion | -9.38% | 1.12x | $760.20 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $2.77 Billion | 13.80% | 0.31x | $1.32 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $127.61 Million | 29.20% | 0.15x | $1.63 Billion |
About Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business cove… Read more